UK-based pharmaceutical company ViiV Healthcare has received US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets.

The approval for the drug will help patients to reduce their weight limit from at least 40kg to at least 30kg in children between six years and less than 12 years to treat HIV-I in children and adolescents.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Dolutegravir will be available for use in two paediatric populations that include paediatric patients who weigh at least 30kg and are living with HIV-I that has not been previously treated, and patients who have been previously treated but have not taken an integrase inhibitor.

ViiV Healthcare chief scientific and medical officer John C. Pottage said: "Through our research and development efforts, corporate social responsibility programmes, partnerships and access initiatives, we have made a difference for younger populations.

"This approval by the FDA provides more children and adolescents the option to be treated with dolutegravir in the US, and supports the global UNAIDS paediatric treatment target."

"This approval by the FDA provides more children and adolescents the option to be treated with dolutegravir in the US, and supports the global UNAIDS paediatric treatment target."

See Also:

The approval is based on a 24-week data collected from the Phase I / II multi-centre open-label P1093 study conducted by ViiV Healthcare in partnership with the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study reveals that treatment with dolutegravir, as well as OBR, has generally been well tolerated and provided efficacy through to week 24 in HIV-I infected children and adolescents between six and 12 years of age and weighing at least 30kg.

In 2014, the pharmaceutical company granted a voluntary licence to the Medicines Patent Pool (MPP) and Aurobindo Pharma to allow the generic production of paediatric formulations of dolutegravir without paying a royalty in 121 countries where most children live with HIV.

Also, ViiV Healthcare is committed to further investigating the ability of dolutegravir to treat younger age-groups affected with HIV-I.